Chimeric antigen receptor macrophages therapy for glioblastoma: challenges and opportunities from preclinical evidence to clinical translation - PubMed
4 hours ago
- #immunotherapy
- #cell therapy
- #glioblastoma
- CAR-M therapy is a promising new treatment for glioblastoma (GBM), leveraging tumor-homing capacity and TME reprogramming.
- Despite preclinical promise, clinical efficacy in GBM remains unproven, highlighting a translational gap.
- Key challenges include target selection, engineering design, and TME-driven issues like phenotypic inactivation and antigen escape.
- Optimization approaches include armoring modifications, logic-gated designs, and convection-enhanced delivery.
- A pragmatic clinical translation pathway emphasizes mechanistic validation, combinatorial approaches, and biomarker analysis.
- The review aims to guide CAR-M therapy from concept to clinical application, balancing opportunities and challenges.